Silo Pharma, Inc. reported its financial results for the fiscal year ending December 31, 2025, revealing total revenues of $72,102, consistent with the previous year. The company, which focuses on developing novel therapeutics for conditions such as PTSD and fibromyalgia, incurred a net loss of $4,227,698, a slight improvement from the $4,392,880 loss reported in 2024. The operating loss from continuing operations decreased to $4,280,662, down from $4,705,694 in the prior year, primarily due to reduced operating expenses.
The company's cost of revenues increased significantly to $44,295 from $5,838, attributed to changes in the amortization of license fees related to its agreements with the University of Maryland and Columbia University. Total operating expenses for 2025 were $4,308,469, a decrease from $4,771,958 in 2024, driven by reductions in compensation, professional fees, and research and development costs. Notably, research and development expenses decreased to $2,160,829 from $2,368,156, reflecting a strategic focus on cost management while continuing to advance its product pipeline.
Silo Pharma is actively pursuing the development of four key product candidates: SPC-15, targeting PTSD and anxiety; SP-26, a ketamine-based implant for fibromyalgia; SPC-14 for Alzheimer’s disease; and SPU-16 for CNS disorders. The company has entered into several exclusive license agreements, including a recent agreement with Medspray Pharma for a nasal spray technology to deliver SPC-15. The company is also engaged in preclinical studies and aims to submit an Investigational New Drug application for SPC-15 in 2026.
As of December 31, 2025, Silo Pharma reported working capital of $6,737,542, an increase from $5,455,483 in 2024, bolstered by cash and cash equivalents of $4,748,700. The company has also initiated a stock repurchase program, authorizing the purchase of up to $1 million of its common stock, which is set to continue until December 31, 2026. Looking ahead, Silo Pharma anticipates increased research and development activities as it seeks to expand its product offerings and navigate the complexities of the biopharmaceutical landscape.
About Silo Pharma, Inc.
Silo Pharma, Inc. is a biopharmaceutical company developing therapies for underserved neurological and psychiatric conditions, including PTSD, anxiety, fibromyalgia, and Alzheimer's disease. Its focus includes traditional drugs and psychedelic formulations like psilocybin and ketamine. The company collaborates with academic institutions, licenses proprietary technologies, and advances drug candidates through preclinical and clinical stages, aiming to address unmet medical needs with innovative delivery methods and targeted treatments.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov